(OTCMKTS : RTSL Rapid Therapeutic Science Laboratories, Inc. Recent News
Rapid Therapeutic Science Laboratories, Inc. (OTCMKTS: RTSL) just announced a Record Order for 100,000 Units of its Metered Dose Inhalers Addressing $9.3 Billion CBD Market
Rapid Therapeutic Science Laboratories, Inc. received an order for a 100,000 unit wholesale order of its Rxoid™ brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream.
Donal R. Schmidt, Jr., Esq., Chairman and CEO stated, “Our Rxoid™ CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States and we are extremely pleased about our products’ acceptance throughout the medical community.”
From additional news today on OTCMKTS:RTSL Rise In CBD and CBG’s Popularity Driven By Combination Of Non-Psychoactive Nature and Therapeutic Properties
The Cannabis plant is made up of more than 100 unique chemical compounds, known as cannabinoids. So far, the two most common and well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC adoption is being boosted by its use in the recreational market, while CBD, thanks to its non-psychoactive nature, is quickly making its way into everything from medicines to edibles to pet food, with U.S. sales of CBD expected to top $23 billion by 2023, according to THCXIndex.com. The article stated: “However, as most industry participants focus their attention on these two cannabinoids – which are here to stay – CBG is rapidly emerging as the third cannabinoid that deserves the attention of investors, especially those in the private equity space, thanks to its rising popularity.” Another article from New Frontier data added: “There’s no escaping it: Right now, CBD is in. Offering the medicinal appeal of cannabis without intoxicating effects, CBD is finding its way into virtually anything. Even after the buzz subsides and the conversation becomes more realistic and nuanced, the cannabinoid is likely to remain a staple of the Health and wellness industry. Of course, THC is not going anywhere either, but they are only two of over 100 cannabinoids identified so far. Industry pros are starting to look to the horizon for what else the incredible plant has to offer.
Rapid Therapeutic Science Laboratories, Inc. Breakthrough Cannabis Device Product
Rxoid is RTSL’s flagship product at this moment and is a breakthrough cannabis device. Rxoid delivers 4 main benefits for the consumer:
- Safe, effective dosing
- Quality ingredients (safest and best relief)
- Fast acting
Rapid Therapeutic Science Laboratories, Inc. OTCMKTS:RTSL Chart
For more about RTSL and their products visit their website https://rtslco.com
Other industry leaders include: Aurora Cannabis Inc. NYSE:ACB, Neptune Wellness Solutions Inc. NASDAQ:NEPT, Cronos Group Inc. NASDAQ:CRON, CV Sciences, Inc. OTCMKTS:CVSI.